Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v3.20.4
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

    As of June 30, 2020     Fair Value Measurements  
    Carrying     Fair     As of June 30, 2020  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:               (unaudited)              
Contingent consideration:                                        
Asuragen (1)   $ 2,861     $ 2,861     $                 -     $           -     $ 2,861  
Other long-term liabilities:                                        
Warrant liability (2)     33       33       -       -       33  
    $ 2,894     $ 2,894     $ -     $ -     $ 2,894  

 

    As of December 31, 2019     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2019  
    Amount     Value     Level 1     Level 2     Level 3  
                               
Liabilities:                                        
Contingent consideration:                                        
Asuragen (1)   $ 2,893     $ 2,893     $             -     $           -     $ 2,893  
Other long-term liabilities:                                        
Warrant liability (2)     82       82       -       -       82  
    $ 2,975     $ 2,975     $ -     $ -     $ 2,975  

 

(1)(2) See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

 

                      Cancellation     Adjustment        
                      of Obligation/     to Fair Value/        
    December 31, 2019     Payments     Accretion     Conversions Exercises     Mark to Market     June 30, 2020  
    (unaudited)  
Asuragen   $ 2,893     $ (308 )   $ 276     $              -     $               -     $ 2,861  
                                                 
Underwriters Warrants     82       -       -       -       (49 )     33  
    $ 2,975     $ (308 )   $ 276     $ -     $ (49 )   $ 2,894